Compare Stryker Corporation (SYK) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs US Bancorp — how do they compare? Stryker Corporation trades at $276.39 (market cap $105.64B), while US Bancorp trades at $57.15 (market cap $87.52B). The key difference: Stryker Corporation is the larger of the two by market cap, and US Bancorp pays the higher dividend (3.85%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 20 Days and US Bancorp for 97 Days on average.
| SYK | USB | |
|---|---|---|
Market Cap | $105.64B | $87.52B |
Volume | 1,918,844 | 9,184,647 |
Sector | Health | Financials |
52-Week High | $388.35 | $65.42 |
52-Week Low | $269.75 | $45.28 |
Typical Hold Time | 20 Days | 97 Days |
Enterprise Value | $117.10B | $117.01B |
Dividend Yield | 1.28% | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $275.4, down 1.11% amid a bearish technical signal and negative news flow. The company maintains strong profitability with a 14.43% net margin and a 71% analyst buy rating, but faces headwinds from a manufacturing issue disclosure that triggered an 8.8% stock drop on September 8, 2026. Q3 2026 earnings are due October 29, 2026, following a mixed earnings history with a recent miss in Q1 2026.
The stock presents a divergence between solid fundamentals and near-term sentiment risks. The consensus price target of $368.11 implies significant upside, but ongoing legal investigations and operational challenges pose risks to investor confidence. Earnings growth and resolution of manufacturing issues are critical for sustained recovery.
U.S. Bancorp (USB) trades at $56.17, down 1.95% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. USB maintains robust profitability with a 27.61% net income margin and attractive valuation metrics including a P/E of 11.21. Recent news highlights dividend increases and positive business momentum in payments and capital markets.
The stock presents a compelling value opportunity with analyst consensus target of $69.94 (24.5% upside), though technical indicators signal near-term caution. Key risks include interest rate sensitivity and regulatory changes, while institutional sentiment remains positive with 51% buy ratings. The upcoming Q3 earnings report will be critical for confirming the positive fundamental trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
